Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of April 10th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for CNOOC, YOFC, AIA, China Life, Xiaomi, Alibaba, 3Sbio, Zijin Gold Intl.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of April 10th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for CNOOC, YOFC, AIA, China Life, Xiaomi, Alibaba, 3Sbio, Zijin Gold Intl.


HK Connect Flows Weekly (Apr 10th): CNOOC, YOFC, AIA, China Life, Xiaomi, Alibaba, 3Sbio

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of April 2nd.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Meituan, BOC, Pop Mart Intl, SMIC, Xiaomi, ICBC, CNOOC, China Life, Alibaba, CK Asset.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of April 2nd.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Meituan, BOC, Pop Mart Intl, SMIC, Xiaomi, ICBC, CNOOC, China Life, Alibaba, CK Asset.


HK Connect Flows Weekly (Apr 2nd): Meituan, BOC, Pop Mart Intl, SMIC, Xiaomi, ICBC, CNOOC

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of March 13th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Tencent, CNOOC, Jiaxin International Resourc, Lingbao Gold, Meituan, Sinopec, CCB, Zijin Mining, HKEx, China Life.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of March 13th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Tencent, CNOOC, Jiaxin International Resourc, Lingbao Gold, Meituan, Sinopec, CCB, Zijin Mining, HKEx, China Life.


HK Connect Flows Weekly (Mar 13th): Tencent, CNOOC, Jiaxin International Resourc, Lingbao Gold

Event-Driven

<ul>
<li>Hang Seng Index Company announced HSCI review results after market close on Feb 13. In our previous note, we reviewed the Sep 2025 HK Connect cycle.</li>
<li>In this note, we provide an update on the forecasted upcoming implementation action by the mainland exchanges based on implementation rules and highlight stock performance thus far.</li>
<li>Our analysis suggests that selectivity will be critical in this cycle, with differentiation driven by pre-positioning, narrative alignment, and ownership structure rather than mechanical inclusion alone.</li>
</ul>


Hang Seng Index Company announced HSCI review results after market close on Feb 13. In our previous note, we reviewed the Sep 2025 HK Connect cycle.
In this note, we provide an update on the forecasted upcoming implementation action by the mainland exchanges based on implementation rules and highlight stock performance thus far.
Our analysis suggests that selectivity will be critical in this cycle, with differentiation driven by pre-positioning, narrative alignment, and ownership structure rather than mechanical inclusion alone.


HK Connect March 2026: Implementation Forecast and Positioning Framework

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Zhejiang Shimai Pharmaceutical / Equity Capital Markets

<ul>
<li>TCE shows strong potential in hematological malignancies, but once it occurs in solid tumors,it is prone to "cytokine storm".It’s not an easy task to capture a share in this market.</li>
<li>To save cash, Shimai has significantly reduced R&amp;D investment, which would delay or even endanger the advancement of key clinical trials, making it difficult to quickly build solid commercialization system.</li>
<li>Compared with <a href="https://www.smartkarma.com/entities/nanjing-leads-biolabs-co-ltd" target="_blank" data-smartkarma-citation="entities:44126:1" rel="noopener">Leads Biolabs,</a> Shimai is at a clear disadvantage in terms of capital, team size, number of candidates in late clinical stages. Valuation would be lower than Leads Biolabs.</li>
</ul>


TCE shows strong potential in hematological malignancies, but once it occurs in solid tumors,it is prone to "cytokine storm".It’s not an easy task to capture a share in this market.
To save cash, Shimai has significantly reduced R&amp;D investment, which would delay or even endanger the advancement of key clinical trials, making it difficult to quickly build solid commercialization system.
Compared with Leads Biolabs, Shimai is at a clear disadvantage in terms of capital, team size, number of candidates in late clinical stages. Valuation would be lower than Leads Biolabs.


Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

China

Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for oncology, autoimmune, and other severe diseases, focusing on unmet medical needs. The company leverages proprietary technology platforms to advance a pipeline of drug candidates, including bispecific antibodies and fusion proteins. Founded in 2012, Leads Biolabs is headquartered in Nanjing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Leads Biolabs (9887 HK)

HK Connect Flows Weekly (Apr 10th): CNOOC, YOFC, AIA, China Life, Xiaomi, Alibaba, 3Sbio

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for CNOOC, YOFC, AIA, China Life, Xiaomi, Alibaba, 3Sbio,...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Apr 2nd): Meituan, BOC, Pop Mart Intl, SMIC, Xiaomi, ICBC, CNOOC

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Meituan, BOC, Pop Mart Intl, SMIC, Xiaomi, ICBC, CNOOC,...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Mar 13th): Tencent, CNOOC, Jiaxin International Resourc, Lingbao Gold

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK), CNOOC (883 HK), Jiaxin International...

Ke Yan, CFA, FRM

HK Connect March 2026: Implementation Forecast and Positioning Framework

March Connect implementation is nearing: we forecast expected ADD/DELETE actions and assess how positioning, crowding, and southbound flows may...

Ke Yan, CFA, FRM

Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

TCE faces challenges in solid tumors due to cytokine storm, Shimai's reduced R&D investment may hinder clinical trials and commercialization,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

HK Connect Flows Weekly (Apr 10th): CNOOC, YOFC, AIA, China Life, Xiaomi, Alibaba, 3Sbio

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for CNOOC, YOFC, AIA, China Life, Xiaomi, Alibaba, 3Sbio,...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Apr 2nd): Meituan, BOC, Pop Mart Intl, SMIC, Xiaomi, ICBC, CNOOC

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Meituan, BOC, Pop Mart Intl, SMIC, Xiaomi, ICBC, CNOOC,...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Mar 13th): Tencent, CNOOC, Jiaxin International Resourc, Lingbao Gold

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK), CNOOC (883 HK), Jiaxin International...

Ke Yan, CFA, FRM

HK Connect March 2026: Implementation Forecast and Positioning Framework

March Connect implementation is nearing: we forecast expected ADD/DELETE actions and assess how positioning, crowding, and southbound flows may...

Ke Yan, CFA, FRM

Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

​TCE faces challenges in solid tumors due to cytokine storm, Shimai's reduced R&D investment may hinder clinical trials and commercialization,...

Xinyao (Criss) Wang

TCE faces challenges in solid tumors due to cytokine storm, Shimai's reduced R&D investment may hinder clinical trials and commercialization,...